offices result in a primary diagnosis of asthma. 2 Moreover, 1.3 million visits to hospital outpatient departments and 1.8 million visits to emergency departments occur as a result of complications caused by asthma. 3, 4 In 439,000 hospitalizations, asthma is the first-listed discharge diagnosis (average length of stay, 3.6 days), 5 and 3404 deaths are caused by asthma annually (1.1 per 100,000). The vast majority of these deaths are preventable. 6 Asthma is a disease not easily con- In certain cases, patients with chronic asthma cannot be differentiated from those with COPD using currently available imaging and lung function testing.
The patients should therefore be treated for both conditions; the management of asthma and COPD should be similar to that of asthma alone. 
Recommended Step for
Step 1 Step 2 Step 3 d
Step 4 The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs. Level of severity is determined by assessment of both impairment and risk. Assess impairment domain by patient's or caregivers' recall of previous 2-4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations (eg, requiring urgent, unscheduled care; hospitalization; intensive care unit admission) with greater underlying disease severity. For treatment purposes, patients who had 2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma. 
Allergen and Irritant
Exposure Control:
Managing the Environment
The National Asthma Control Initiative advises the following:
Clinicians should review each patient's exposure to allergens and irritants and provide a multipronged strategy to reduce exposure to those allergens and irritants to which a patient is sensitive and exposed, that is, that make a patient's asthma worse. 12 Figure 1 shows the available methods for asthma management. 
Long-Term Control Medications
Corticosteroids: Block late-phase reaction to allergen, reduce airway hyperresponsiveness, and inhibit inflammatory cell migration and activation. They are the most potent and effective anti-inflammatory medications currently available (Evidence A). ICSs are used in the long-term control of asthma. Short courses of oral systemic corticosteroids are often used to gain prompt control of the disease when initiating long-term therapy; long-term oral systemic corticosteroids are used for severe persistent asthma.
Cromolyn sodium and nedocromil: Stabilize mast cells and interfere with chloride channel function. They are used as alternative, but not preferred, medication for the management of mild persistent asthma (Evidence A). They can also be used as preventive treatment prior to exercise or unavoidable exposure to known allergens.
Immunomodulators: Omalizumab (anti-lgE) is a monoclonal antibody that prevents binding of IgE to the high-affinity receptors on basophils and mast cells. Omalizumab is used as adjunctive therapy for patients aged ≥12 y who have allergies and severe persistent asthma (Evidence B). Clinicians who administer omalizumab should be prepared and equipped to identify and treat anaphylaxis that may occur.
LABAs: Salmeterol and formoterol are bronchodilators that have a duration of bronchodilation of at least 12 h after a single dose.
LABAs are not to be used as monotherapy for long-term control of asthma (Evidence A).
LABAs are used in combination with ICSs for long-term control and prevention of symptoms in moderate or severe persistent asthma (step 3 care or higher in children aged ≥5 y and adults) (Evidence A for ages ≥12 y, Evidence B for ages 5-11 y).
Of the adjunctive therapies available, LABA is the preferred therapy to combine with ICS in youths aged ≥12 y and adults (Evidence A).
In the opinion of the Expert Panel, the beneficial effects of LABA in combination therapy for the great majority of patients who require more therapy than low-dose ICS alone to control asthma (ie, require step 3 care or higher) should be weighed against the increased risk of severe exacerbations, although uncommon, associated with the daily use of LABAs.
For patients aged ≥5 y who have moderate persistent asthma or asthma inadequately controlled on low-dose ICS, the option to increase the ICS dose should be given equal weight to the option of adding LABA.
For patients aged ≥5 y who have severe persistent asthma or asthma inadequately controlled on step 3 care, the combination of LABA and ICS is the preferred therapy.
LABA may be used before exercise to prevent EIB (Evidence A), but duration of action does not exceed 5 h with chronic regular use. Frequent and chronic use of LABA for EIB is discouraged, because this use may disguise poorly controlled persistent asthma (Evidence D).
In the opinion of the Expert Panel, the use of LABA for the management of acute symptoms or exacerbations is not currently recommended (Evidence D).
Leukotriene modifiers: Include LTRAs and a 5-lipoxygenase inhibitor. Two LTRAs are available: montelukast (for patients aged >1 y) and zafirlukast (for patients aged ≥7 y). The 5-lipoxygenase pathway inhibitor zileuton is available for patients aged ≥12 y; liver function monitoring is essential. LTRAs are alternative, but not preferred, therapy for the management of mild persistent asthma (step 2 care) (Evidence A). LTRAs can also be used as adjunctive therapy with ICSs, but for youths aged ≥12 y and adults they are not the preferred adjunctive therapy compared with the addition of LABAs (Evidence A). Zileuton can be used as alternative but not preferred adjunctive therapy in adults (Evidence D).
Methylxanthines: Sustained-release theophylline is a mild to moderate bronchodilator used as alternative, not preferred, adjunctive therapy with ICS (Evidence A). Theophylline may have mild anti-inflammatory effects.
Monitoring of serum theophylline concentration is essential.
Quick-Relief Medications
Anticholinergics: Inhibit muscarinic cholinergic receptors and reduce intrinsic vagal tone of the airway. Ipratropium bromide provides additive benefit to SABA in moderate-to-severe asthma exacerbations. May be used as an alternative bronchodilator for patients who do not tolerate SABA (Evidence D).
SABAs: Albuterol, levalbuterol, and pirbuterol are bronchodilators that relax smooth muscle. Therapy of choice for relief of acute symptoms and prevention of EIB (Evidence A).
Systemic corticosteroids:
Although not short acting, oral systemic corticosteroids are used for moderate and severe exacerbations as adjunct to SABAs to speed recovery and prevent recurrence of exacerbations (Evidence A). Abbreviations: EIB, exercise-induced bronchospasm; ICS, inhaled corticosteroid; Ig, immunoglobulin; LABA; long-acting β-agonist; LTRA, leukotriene receptor agonist; SABA, short-acting β-agonist.
Step 1
Preferred: SABA PRN
Step Step up if needed (first, check adherence, environmental control, and comorbid conditions)
ASSESS CONTROL
Step down if possible (and asthma is well controlled at least 3 months)
Intermittent Asthma Persistent Asthma: Daily Medication
Consult with asthma specialist if step 4 care or higher is required. Consider consultation at step 3.
Each
Step: Patient education, environmental control, and management of comorbidities.
Steps 2-4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma. Stepwise approach for managing asthma in patients aged ≥12 years. The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs. If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up.
Step 1, 2, and 3 preferred therapies are based on Evidence A; step 3 alternative therapy is based on Evidence A for LTRA, Evidence B for theophylline, and Evidence D for zileuton.
Step 4 preferred therapy is based on Evidence B, and alternative therapy is based on Evidence B for LTRA and theophylline and Evidence D zileuton.
Step 5 preferred therapy is based on Evidence B.
Step 6 preferred therapy is based on Expert Panel Report 2 (1997) and Evidence B for omalizumab. Immunotherapy for steps 2-4 is based on Evidence B for house-dust mites, animal dander, and pollens; evidence is weak or lacking for molds and cockroaches. Evidence is strongest for immunotherapy with single allergens. The role of allergy in asthma is greater in children than in adults.
Footnotes:
a Theophylline requires monitoring of serum concentration levels. b Zileuton is a less desirable alternative because of limited studies as adjunctive therapy and the need to monitor liver function. c Clinicians who administer immunotherapy or omalizumab should be prepared and equipped to identify and manage anaphylaxis that may occur. d In step 6, before oral corticosteroids are introduced, a trial of high-dose ICS + LABA + either LTRA, theophylline, or zileuton may be considered, although this approach has not been studied in clinical trials.
Abbreviations: EIB, exercise-induced bronchospasm; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LTRA, leukotriene receptor agonist; SABA, short-acting β-agonist.
In general, patient visits should be scheduled at 2-to 6-week intervals while initiating therapy or stepping up therapy to achieve control; 1-to 6-month intervals after asthma control is achieved to monitor whether asthma control is maintained; and at 3-month intervals if a stepdown in therapy is anticipated.
17 Table 2   7 shows the recommended methods for 
3-WEEK FOLLOW-UP
Henry continued to follow his asthma action plan. Having the plan at hand allowed him to return to his normal activities, including performing his regular duties at work.
3-AND 6-MONTH FOLLOW-UP
Henry reported continued asthma con- The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.
Recommended Action
Maintain current step.
Step At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care; hospitalization; intensive care unit admission) indicate poorer disease control. For treatment purposes, patients who had ≥2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma. See Figure 2 for steps. The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs. Level of control is based on the most severe impairment or risk.
e Before step up in therapy, review adherence to medication, inhaler technique, environmental control, and comorbid conditions. If an alternative treatment option was used in a step, discontinue and use the preferred treatment for that step.
Abbreviations: EIB, exercise-induced bronchospasm; FEV 1 , forced expiratory volume in 1 second; NA, not applicable; SABA, short-acting β-agonist. 
Conclusion
In patients with suspected asthma, spirometric testing is important in establishing the diagnosis. 7 The proper assessment and management of asthma is essential to patients' quality of life and well-being. 
